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Introduction
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, has been shown to play a critical role in both normal physiological and pathological processes. It is essential during development and wound healing, and is tightly regulated by endogenous pro-and antiangiogenic factors. It has also been implicated in a number of diseases including cancer, rheumatoid arthritis and macular degeneration (1) (2) (3) . Since the angiogenesis hypothesis was first proposed by Judah Folkman in 1971 (4), a number of angiogenesis inhibitors have been discovered and developed into anti-angiogenic drugs (5) (6) (7) . A monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab, was first approved by the US-Food and Drug Administration (FDA) in 2004 for the treatment of metastatic colon cancer in combination with standard chemotherapy (8) . Subsequently, several small molecule angiogenesis inhibitors have been entered the clinic, including sorafenib (Nexavar®), sunitinib (Sutent®) and pazopanib (Votrient®). However, most of these small molecule antiangiogenic drugs are kinase inhibitors that lack specificity or lead to a high frequency of drug resistance (9) (10) (11) , necessitating the development of small molecule angiogenesis inhibitors with novel mechanisms of action.
In an effort to accelerate drug discovery and development, we assembled the Johns Hopkins Drug Library over a decade ago and screened it for new anti-angiogenic activity among existing drugs using a proliferation assay with primary human umbilical vein endothelial cells.
Among the most interesting hits was the antifungal drug itraconazole (12) . Interestingly, itraconazole was also found to be an inhibitor of the hedgehog signaling pathway in a separate screen, rendering itraconazole a novel anticancer drug candidate capable of inhibiting the growth of both tumor vasculature and tumor cells themselves (13) . A series of tests of itraconazole in preclinical angiogenesis and cancer models confirmed the anti-angiogenic and anticancer activity of itraconazole in vivo (12) (13) (14) . Based on these promising preclinical results, itraconazole entered multiple Phase II human clinical studies for treating different types of cancer.
(http://www.clinicaltrials.gov/). Positive clinical results have been reported for advanced lung cancer, metastatic prostate cancer and basal cell carcinoma (15) (16) (17) . Moreover, itraconazole was found to increase progression or overall survival among late-stage ovarian, triple-negative breast and metastatic pancreatic cancer patients upon retrospective analysis of previous clinical data 6 (18) (19) (20) (21) . Together, these encouraging results strongly suggest that itraconazole is a promising new anticancer drug lead.
Although the precise mechanism for the antiangiogenic and anti-hedgehog activities remains unknown, preliminary evidence suggests that the mode of action of itraconazole is distinct from any other known inhibitors of angiogenesis or the hedgehog signaling pathway.
Early on, we ruled out the cholesterol biosynthetic enzyme, lanosterol 14α-demethylase, which mediates the antifungal activity of itraconazole, as the relevant target for its antiangiogenic activity (12) . Subsequently, we serendipitously discovered that itraconazole blocks the traffic of cholesterol and likely lipids out of the lysosome, causing a phenotype similar to Niemann-Pick Disease Type C (NPC) in endothelial cells. We also found that itraconazole is a potent inhibitor of the mTOR pathway in endothelial cells (22) . Importantly, the blockade of cholesterol trafficking through the endolysosome can only partially explain the inhibition of mTOR by itraconazole, suggesting that there exist unidentified molecular target(s) for itraconazole.
Similarly, the mechanism underlying the inhibition of hedgehog signaling also remains unclear, even though it has been shown to block the translocation of Smoothened from intracellular vesicles into the primary cilium (13) . Using a number of synthetic analogs of itraconazole, we explored the structure-activity relationship of itraconazole for its two distinct activities and found no correlation between the two, further suggesting that the antiangiogenic and anti-hedgehog activity of itraconazole are likely to be mediated by different molecular mechanisms (23) .
Itraconazole has been widely used to treat fungal infections. Although itraconazole is known to be relatively well-tolerated, about 7% of patients who received the drug experience hepatotoxicity (24) . In addition to lanosterol 14 alpha-demethylase (25) , itraconazole is also known to be a potent inhibitor of human liver cytochrome P450 3A4 (CYP3A4), accounting for its extensive drug-drug interactions with other medications (26) . It is believed that the effect of itraconazole on CYP3A4 is responsible for the human hepatotoxicity (27) . The commercial itraconazole consists of four cis-stereoisomers of itraconazole, including IT-A (2S,4R,2'R), IT-B (2R,4S,2'R), IT-C (2S,4R,2'S), and IT-D (2R,4S,2'S). All four isomers are known to be ligands of CYP3A4 (28) . However, only IT-B and IT-D among the four isomers were metabolized by CYP3A4 (28) . To assess the antiangiogenic activity of the different stereoisomers, we previously synthesized each of cis-stereoisomers and determined their effects on both fungi and endothelial
Research. (29) . In this study, we conducted a large-scale purification of each stereoisomer from the racemic itraconazole mixture using the preparative supercritical fluid chromatography (SFC) and obtained gram quantities of each purified stereoisomer. Using the purified stereoisomers, we compared the antiangiogenic activity and hepatotoxicity of each stereoisomer of itraconazole and the racemic itraconazole both in vitro and in vivo. We found that IT-A and IT-C are more potent at inhibiting angiogenesis compared to the others, whereas IT-C and IT-D are less hepatotoxic compared to IT-A, IT-B and racemic itraconazole. Together, these results suggest that IT-C is the most potent antiangiogenic and anticancer agent with the least hepatotoxicity among the four stereoisomers of itraconazole.
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Materials and Methods

Cells
Human umbilical vein endothelial cells (HUVEC) (Lonza, Allendale, NJ) were grown in endothelial cell growth medium-2 (EGM-2) using the EGM-2 bullet kit (Lonza) per manufacturer's instructions. HUVEC phenotype was verified by morphological observation throughout serial passage by the manufacturer. Human pericytes (placental derived) were purchased from Zen-Bio (Research Triangle Park, NC) and were grown in the complete pericyte growth medium (Zen-Bio). HCC1954 human breast cancer and CWR22Rv1 human prostate cancer cells were grown in RPMI-1640 medium containing 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA) and 1% antibiotic (penicillin and streptomycin) solution (Invitrogen).
The cells were maintained in a humidified incubator at 37 °C adjusted to 5% CO 2 .
Reagents
Racemic itraconazole and filipin were purchased from Sigma-Aldrich (St Louis, MO). Four individual cis-stereoisomers of itraconazole (IT-A, IT-B, IT-C and IT-D) were obtained using preparative supercritical fluid chromatography (SFC) separation of commercial itraconazole, which was performed by WuXi AppTec (Shanghai, China). Quality control of each purified stereoisomer was conducted by chiral HPLC and optical rotation using previously synthesized stereoisomer samples as standards (29) . Low-density lipoprotein (LDL) from human plasma was purchased from Fisher Scientific (Pittsburgh, PA).
HUVEC proliferation assay
HUVEC (5000 cells per well) were seeded in 96-well plates containing 0.2 mL of EGM-2 medium and allowed to adhere at 37 °C for 24 hours. The cells were then treated with various concentrations of each compound for 24 hours. Cells were pulsed with 0.5 μCi [ 
HUVEC tube formation assay
The tube formation assay, a model for assessment of angiogenesis in vitro, was conducted as previously described (30) 
HUVEC-pericyte co-culture tube formation
Growing pericytes in a 6-cm cell culture dish were labeled with Calcein-AM for 30 min prior to the tube formation experiments. Ibidi µ-Slide angiogenesis chamber (Ibidi, Planegg, Germany) was coated with Matrigel by adding 10 μl of ice-cold Matrigel solution per well followed by incubation at 37°C for 1 hour. HUVEC (1.5 × 10
Determination of hepatotoxicity in primary human hepatocytes
Fresh primary human hepatocytes (6-well plates) with matrigel overlay from three donors were obtained from XenoTech, LLC (Lenexa, KS). Ages and genders of donors were as follows: 22 year old male, 54 year old male and 63 year old male. Hepatocyte viability from each donor was at least 74%. Upon receipt of the hepatocytes, the shipping medium was replaced with Williams' Medium E supplemented with 10% fetal bovine serum (Invitrogen), penicillin-streptomycin (Sigma-Aldrich) and L-glutamine (Invitrogen). The hepatocytes were then incubated overnight at 37°C in a 5% CO 2 A cross-section of the tumor tissue was photographed at magnification ×100 under the Nikon Eclipse TS100 microscope and blood vessels stained with anti-CD31 antibody were counted per field for the quantification of tumor angiogenesis. The lumen sizes of the blood vessels were also quantified using the Zen image analysis tool (Carl Zeiss).
Statistical analysis
Statistical analysis of the data was performed using GraphPad Prism version 5.0. Statistical significance, determined by two-tailed Student's t-test (between two groups) and two-tailed Single Sample t-test (test group vs hypothetical control value), is indicated throughout by the following: * , P ≤ 0.05 and * * , P ≤ 0.01.
Results
Racemic itraconazole and its stereoisomers inhibited HUVEC proliferation with different potencies.
Racemic itraconazole and each of the four purified cis-stereoisomers were tested for HUVEC proliferation by measuring the ability of the cells to incorporate [ (Table 1) .
Itraconazole stereoisomers inhibited VEGFR2 glycosylation, mTOR activity and cholesterol trafficking in HUVEC.
We next determined if all stereoisomers still share a common mechanism of action to inhibit endothelial cell proliferation by assessing three previously identified activities of itraconazole, i.e., inhibition of VEGFR2 glycosylation, mTOR and cholesterol trafficking (NPC phenotype).
Itraconazole inhibited VEGFR2 glycosylation in HUVEC as evidenced by the dose-dependent shift of high-molecular weight, hyper-glycosylated form of VEGFR2 to the low molecular weight, hypo-glycosylated form. All four stereoisomers inhibited VEGFR2 glycosylation with slight different potencies. All four stereoisomers as well as racemic itraconazole dosedependently inhibited mTOR activity as measured by S6 kinase (S6K) phosphorylation, a downstream target of mTOR. It was apparent that IT-A and IT-C (2S4R series) were more potent than IT-B and IT-D (2R4S series) for the inhibition of VEGFR2 glycosylation and mTOR activity (Fig. 1A) . Next, we determined the effects of itraconazole and the stereoisomers on (Fig. 1B) . At concentrations over 100 nmol/L, IT-B and IT-D were able to induce an NPC phenotype in HUVEC (data not shown). Thus, for inhibition of cholesterol trafficking, mTOR activity and VEGFR2 glycosylation, 2S4R series were more potent than 2R4S series, which correlated with the relative potency of the stereoisomers against HUVEC proliferation.
Inhibition of angiogenesis by itraconazole stereoisomers is dependent on cholesterol.
We next employed an in vitro tube formation assay to assess the activity of the stereoisomers. Fig. S2A and B) . As the antiproliferative activity of itraconazole was shown to be dependent on cholesterol trafficking (22), we conducted a rescue experiment of angiogenesis inhibition by itraconazole and stereoisomers with low-density lipoprotein (LDL). Treatment of HUVEC with LDL slightly enhanced the tube formation of HUVEC. When HUVEC was treated with itraconazole or stereoisomers together with LDL, the inhibition of tube formation was completely reversed to the control level ( Fig. 1C and D) . glycosylation by itraconazole or stereoisomers was also completely reversed by LDL (Fig. 1E and F). These results indicated that, similar to itraconazole, the antiangiogenic activity of the different stereoisomers is dependent on their ability to inhibit cholesterol trafficking.
Racemic itraconazole and its stereoisomers inhibited HUVEC-pericyte co-culture tube formation.
Pericytes are vascular supporting cells that interact with endothelial cells and play an important role in initiation of angiogenesis by guiding the endothelial cell sprouting and stabilizing the vessels (33) . Therefore, pericytes, together with endothelial cells, have been recognized as a putative target in cancer treatment (34) . To examine the effects of racemic itraconazole and its stereoisomers on pericyte angiogenesis, we performed pericyte alone and pericyte-HUVEC coculture tube formation experiments. Under our experimental conditions, and as shown in other reports, pericytes alone could not form tubular networks on Matrigel (data not shown) (35) . We therefore used HUVEC-pericyte co-culture tube formation at a ratio of 30:1 of HUVEC and pericytes, respectively. At a concentration of 3 μmol/L, racemic itraconazole, IT-A and IT-C significantly inhibited pericyte tube networks as well as overall co-culture tube formation on Matrigel ( Fig. 2A and B) . In contrast, IT-B and IT-D showed negligible effects on co-culture tube formation. These results indicated that racemic itraconazole and the two stereoisomers IT-A and IT-C inhibited angiogenesis in the presence of pericytes.
Itraconazole stereoisomers possess distinct hepatotoxicity profiles.
Having shown that the 2S4R pair of itraconazole stereoisomers are more potent than 2R4S pair in all in vitro angiogenesis-related assays, we wondered whether the stereochemistry had a similar influence on the relative hepatotoxicity of the different stereoisomers. Using freshly prepared human primary hepatocytes, we determined three representative markers of hepatotoxicity, including hepatocyte death, intracellular GSH depletion and alanine transaminase (ALT) release. As expected, incubation with 2 and 10 µmol/L itraconazole increased primary human hepatocyte death 1.6-and 1.8-fold (P ≤ 0.01), respectively, as compared to vehicle (Fig. 3A) . Similarly, itraconazole effects on GSH depletion (76%; P ≤ 0.01) and ALT levels in the cell culture medium (92.5 IU/L; P ≤ 0.01) were consistent with the hepatotoxicity (Fig. 3B and C) . Interestingly, IT-A and IT-B (both have a 2'R stereochemistry) appeared to have slightly higher hepatotoxicity than racemic itraconazole as judged by induction of cell death by 2.2-(P ≤ 0.01) and 2.0-fold (P ≤ 0.01), respectively, at a final concentration of 10 µmol/L as well as increases in GSH depletion (70% (P ≤ 0.01) and 67% (P ≤ 0.01), respectively) and extracellular ALT levels (117 IU/L (P ≤ 0.01) and 128 IU/L (P ≤ 0.01), respectively). In contrast, IT-C and IT-D (both have a 2'S stereochemistry) did not show appreciable hepatotoxicity, as judged by cell death, hepatic GSH levels or the concentration of ALT in the culture medium (Fig.   3A-C) . These results were quite unexpected as the hepatotoxicity profile is totally different from the antiangiogenic profile of stereoisomers. Thus, the stereochemistry at the C2 and C4 chiral centers of itraconazole appeared to be important for the antiangiogenic activity while that of the C2' chiral center influences hepatotoxicity (the chemical structure of itraconazole is shown in Table 1 ).
We next assessed the hepatotoxicity of the stereoisomers in mice. Female mice were administered with vehicle or itraconazole stereoisomers (60 mg/kg) i.p. once daily for 10 days.
After drug treatment, we first determined the ALT levels in the blood samples of the mice, but found no significant change in blood ALT levels from the mice treated with stereoisomers (data not shown). Next, livers from each mouse were isolated and processed for H&E staining. The livers from vehicle or IT-C treated mice appeared normal, while those from IT-A treated mice showed abnormalities, i.e., white colored and quite sticky to surrounding tissues. In comparison, livers in mice treated with itraconazole looked partially abnormal (data not shown). From the H&E staining of the liver sections, we found that IT-A caused severe fatty liver in the mice (Fig.   3D ). Mice treated with racemic itraconazole had partial fatty liver, while livers from those treated with vehicle or IT-C were normal (Fig. 3D) . Once again, IT-C showed less hepatotoxicity in mice than either IT-A or the racemic itraconazole, consistent with the results from human hepatocytes.
IT-C inhibited angiogenesis in vivo.
Research. inhibition at 20 mg/kg and 50 mg/kg, respectively ( Fig. 4A and B) . Similar results were observed in NG2-positive pericyte staining. IT-C exhibited the strongest inhibition on the infiltration and vessel formation by NG2-positive pericytes, with 47% and 70% inhibition at 20 mg/kg and 50 mg/kg, respectively ( Fig. 4C and D) . These results suggested that IT-C is more active than IT-A for the antiangiogenic activity.
IT-C inhibited tumor growth and tumor-induced angiogenesis in mice.
Taking into consideration both the antiangiogenic activity and hepatotoxicity, IT-C was deemed superior to all other stereoisomers due to a combination of its higher antiangiogenic potency and lack of hepatotoxicity in both human cells and mice. We thus assessed the antitumor activity of IT-C in two tumor xenograft models (breast cancer and prostate cancer) in parallel with racemic itraconazole. We also took the opportunity to determine the effect of IT-C on tumor-induced growth of HCC1954 xenografts compared to the vehicle alone (Fig. 5A) . Tumor volume was reduced by 40% at Day 28 of treatment with 50 mg/kg itraconazole compared to the vehicle control. Importantly, IT-C showed more pronounced inhibition of the tumor xenograft growth than itraconazole at both 25 and 50 mg/kg (Fig. 5B) . It inhibited the tumor volume by 53% at Day 28 at 50 mg/kg. There were no apparent toxicities associated with itraconazole or IT-C based on assessment of mouse body weight (Supplementary Fig. S4 ). Similar results were observed in the CWR22Rv1 prostate cancer xenograft model. Treatment of male athymic nude mice with either itraconazole (60 mg/kg) or IT-C (60 mg/kg) significantly inhibited the tumor growth ( Fig. 5C and D) . To assess tumor-associated angiogenesis in the breast cancer xenografts, the tumor tissues were harvested from the mice and processed for immunohistochemical analysis of CD31, a blood vessel marker. Compared to the vehicle, both racemic itraconazole and IT-C significantly inhibited angiogenesis in the HCC1954 xenografts ( Fig. 5E and F) , with IT-C being more potent than itraconazole.
Discussion
Although itraconazole has been widely used to treat fungal infections, several adverse effects have been reported. The most frequent side effects associated with itraconazole are gastrointestinal complaints including nausea, vomiting, diarrhea, flatulence and constipation (36) .
Fortunately, these adverse effects are mostly transient and mild, and thus are tolerable to patients (37). However, rare but severe hepatoxicity associated with itraconazole has also been reported.
Up to 7% of patients receiving itraconazole have elevated ALT levels (24) . Moreover, fatalities due to hepatic failure have been reported in patients receiving itraconazole (38). Major efforts have been made to overcome the adverse effects of itraconazole on the liver. A pulse therapy of itraconazole (typically, 400 mg itraconazole b.i.d. for 1 week followed by a three-weeks holiday) was introduced in superficial fungal infections based on the pharmacokinetic (PK) properties of itraconazole (39) . Upon cessation of drug intake, itraconazole is rapidly cleared from systemic circulation (7-10 days), but persists for 3-4 weeks in the stratum corneum and for up to 6-12 months in the nail (40) . This PK property of itraconazole makes pulse therapy for onychomycosis and dermatomycoses possible, which could significantly reduce the hepatotoxicity-related adverse effects while showing therapeutic efficacies similar to continuous therapy (41) . However, this strategy may not be applicable for the cancer therapy, which requires a high dose of itraconazole in systemic circulation. Thus, the hepatotoxicity associated with itraconazole still poses a significant challenge for the long-term, high-dose treatment of cancer patients with itraconazole.
Hepatotoxicity associated with itraconazole has long been recognized, but the mechanism underlying the liver toxicity of itraconazole has remained obscure. Cytochrome P450, specifically CYP3A4, is a main liver enzyme responsible for the metabolism of itraconazole (42) .
Itraconazole also inhibits the enzyme activity of CYP3A4 (26) . When rats were pretreated with phenobarbital, an inducer of cytochrome P450, hepatotoxicity induced by itraconazole was significantly reduced (27, 37) . On the other hand, pretreatment of rats with SKF 525A, an inhibitor of cytochrome P450, significantly enhanced itraconazole-induced hepatoxicity (27) .
These results suggest that inhibition of cytochrome P450, probably CYP3A4, by itraconazole is, at least in part, responsible for itraconazole-induced hepatotoxicity. Commercial itraconazole currently used in the clinic is a racemic mixture of four cis-stereoisomers. It is interesting to note These results suggest that inhibition of CYP3A4 by itraconazole or metabolism of itraconazole by CYP3A4 may not be solely responsible for its hepatotoxicity. One interesting possibility is that a cytochrome P450 enzyme with specificity for the C2' chiral center of itraconazole could be the main enzyme mediating the hepatotoxicity of itraconazole. In addition, the segregation of antiangiogenic activity and hepatotoxicity of the four stereoisomers of itraconazole suggests that the cellular target protein(s) responsible for angiogenesis inhibition and hepatotoxicity might be different. Answers to these questions may become clear upon identification of the molecular targets mediating the different effects of itraconazole.
Although itraconazole was shown to elevate serum ALT levels in rats, it did not increase the levels in mice in this study. Instead, itraconazole and IT-A induced moderate to severe fatty liver in mice. Rats and mice have shown different hepatotoxicity responses to certain compounds, such as coumarin (43) . Inter-strain differences of hepatotoxicity responses have also been observed in mice treated with cocaine and phenobarbital (44) . This is thought to be due to the different liver metabolic enzymes present in different strains and animal species. Itraconazole has shown similar hepatotoxicity profiles in humans and rats, suggesting that they respond similarly to this compound. In mice, the compound did not show ALT elevation, but induced fatty liver, suggesting that racemic itraconazole and IT-A still have negative impact on mice liver but in a way different from rats or humans. However, IT-C at doses up to 60 mg/kg did not cause apparent adverse effects on the mouse liver. In the experiments using human primary hepatocytes, IT-C showed no apparent signs of hepatotoxicity at concentrations up to 10 µmol/L for all three hepatotoxicity markers. In contrast, IT-A was strongly hepatotoxic and racemic itraconazole showed a medium degree of hepatotoxicity. Together, these results points to IT-C as Research.
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